- Home
- WKHS vs KZIA Comparison
WKHS vs KZIA Comparison
Compare WKHS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKHS
- KZIA
- Stock Information
- Founded
- WKHS 2007
- KZIA 1994
- Country
- WKHS United States
- KZIA Australia
- Employees
- WKHS N/A
- KZIA N/A
- Industry
- WKHS Auto Manufacturing
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- WKHS Consumer Discretionary
- KZIA Health Care
- Exchange
- WKHS Nasdaq
- KZIA Nasdaq
- Market Cap
- WKHS 6.0M
- KZIA 5.1M
- IPO Year
- WKHS N/A
- KZIA 1999
- Fundamental
- Price
- WKHS $0.94
- KZIA $5.65
- Analyst Decision
- WKHS Hold
- KZIA Strong Buy
- Analyst Count
- WKHS 1
- KZIA 2
- Target Price
- WKHS $15.62
- KZIA $57.50
- AVG Volume (30 Days)
- WKHS 704.0K
- KZIA 24.6K
- Earning Date
- WKHS 05-15-2025
- KZIA 06-17-2025
- Dividend Yield
- WKHS N/A
- KZIA N/A
- EPS Growth
- WKHS N/A
- KZIA N/A
- EPS
- WKHS N/A
- KZIA N/A
- Revenue
- WKHS $5,917,985.00
- KZIA $1,655,324.00
- Revenue This Year
- WKHS $54.16
- KZIA N/A
- Revenue Next Year
- WKHS $85.00
- KZIA N/A
- P/E Ratio
- WKHS N/A
- KZIA N/A
- Revenue Growth
- WKHS N/A
- KZIA 248000.00
- 52 Week Low
- WKHS $0.81
- KZIA $2.86
- 52 Week High
- WKHS $50.00
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- WKHS 41.36
- KZIA 78.10
- Support Level
- WKHS $0.88
- KZIA $3.54
- Resistance Level
- WKHS $0.95
- KZIA $4.00
- Average True Range (ATR)
- WKHS 0.08
- KZIA 0.50
- MACD
- WKHS 0.04
- KZIA 0.25
- Stochastic Oscillator
- WKHS 44.50
- KZIA 86.07
About WKHS Workhorse Group Inc.
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.